Join our daily newsletter At The Bell to receive exclusive market insights
- Nyrada’s (NYR) new lead drug candidate has advanced to efficacy studies with the Walter Reed Army Institute of Research (WRAIR)
- The company says its new drug, NYR-BI01, is more potent than its predecessor
- The new candidate displayed high potency in a biological assay and impressive characteristics during a pharamacokinetic study, indicating that the drug can be well-tolerated
- Nyrada is down 3.17 per cent, trading at 30.5 cents at 1:00 pm AEST
Nyrada’s (NYR) new lead drug candidate has advanced to efficacy studies with the Walter Reed Army Institute of Research (WRAIR).
The company says its new drug, NYR-BI01, is more potent than its predecessor, NYX-1010.
Nyrada says the new candidate showed high potency in a biological assay and impressive characteristics during a pharamacokinetic study, intended to determine the level at which it penetrates the brain.
In the study, the treatment was administered to uninjured animals via continuous intravenous infusion at two doses for 72 hours, assessing blood concentrations and brain penetration — a duration that aligns with the therapeutic window for preventing secondary brain injury in patients.
The company says no adverse effects were observed in the animals at either dose level, and no significant changes were observed in markers of liver and kidney function or body weight, indicating that the drug is well-tolerated even at the higher dose.
“Crossing the blood-brain-barrier at above therapeutic levels with a newly improved and highly potent drug candidate means our drug can reach the area of the brain damaged by traumatic brain injury,” said Nyrada CEO James Bonnar.
“This focus on optimising our drug in preclinical studies enables us to take the best candidate into our studies with WRAIR and eventually into human clinical trials, giving us the best chance of success in Phase I.”
Nyrada is down 3.17 per cent, trading at 30.5 cents at 1:00 pm AEST.
